{"id":12731,"date":"2023-10-19T21:34:00","date_gmt":"2023-10-19T13:34:00","guid":{"rendered":"https:\/\/flcube.com\/?p=12731"},"modified":"2024-11-14T21:43:00","modified_gmt":"2024-11-14T13:43:00","slug":"pharmaron-beijing-to-establish-singapore-jv-rxilient-biohub-for-cdmo-services","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=12731","title":{"rendered":"Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services"},"content":{"rendered":"\n<p>China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/3759:HKG\">HKG: 3759<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/300759:SHE\">SHE: 300759<\/a>) has announced plans to invest USD 10.5 million in establishing a joint venture (JV) named Rxilient Biohub Pte. Ltd. in Singapore. This strategic move marks Pharmaron&#8217;s expansion into the Southeast Asian market, aiming to provide high-quality CDMO services in the region.<\/p>\n\n\n\n<p><strong>JV Partners and Investment Details<\/strong><br>The JV is being established in partnership with China Medical System Holdings Ltd (CMS; HKEX: 0867), Rxilient Health Pte. Ltd, and Healthy Goal Limited. Collectively, the involved firms will contribute a total of USD 30 million towards the manufacturing and operational costs of Rxilient Biohub. This significant investment underscores the commitment of the partners to enhance CDMO service capabilities in Singapore and beyond.<\/p>\n\n\n\n<p><strong>Focus on CDMO Services<\/strong><br>Rxilient Biohub Pte. Ltd. will specialize in providing CDMO services, leveraging the expertise and resources of its parent companies. The establishment of this JV in Singapore is expected to strengthen the biopharmaceutical supply chain in the region, offering advanced manufacturing solutions to clients and contributing to the growth of the local biotech industry.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[19,20,1501,768,2085,1502],"class_list":["post-12731","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cro-cmo-cdmo","tag-finance","tag-hkg-3759","tag-pharmaron","tag-rxilient-biohub","tag-she-300759"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced plans to invest USD 10.5 million in establishing a joint venture (JV) named Rxilient Biohub Pte. Ltd. in Singapore. This strategic move marks Pharmaron&#039;s expansion into the Southeast Asian market, aiming to provide high-quality CDMO services in the region.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=12731\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=12731\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-19T13:34:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-14T13:43:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12731#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12731\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services\",\"datePublished\":\"2023-10-19T13:34:00+00:00\",\"dateModified\":\"2024-11-14T13:43:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12731\"},\"wordCount\":192,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"Finance\",\"HKG: 3759\",\"Pharmaron\",\"Rxilient Biohub\",\"SHE: 300759\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12731#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12731\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=12731\",\"name\":\"Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-10-19T13:34:00+00:00\",\"dateModified\":\"2024-11-14T13:43:00+00:00\",\"description\":\"China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced plans to invest USD 10.5 million in establishing a joint venture (JV) named Rxilient Biohub Pte. Ltd. in Singapore. This strategic move marks Pharmaron's expansion into the Southeast Asian market, aiming to provide high-quality CDMO services in the region.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12731#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12731\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12731#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced plans to invest USD 10.5 million in establishing a joint venture (JV) named Rxilient Biohub Pte. Ltd. in Singapore. This strategic move marks Pharmaron's expansion into the Southeast Asian market, aiming to provide high-quality CDMO services in the region.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=12731","og_locale":"en_US","og_type":"article","og_title":"Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=12731","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-10-19T13:34:00+00:00","article_modified_time":"2024-11-14T13:43:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=12731#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=12731"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services","datePublished":"2023-10-19T13:34:00+00:00","dateModified":"2024-11-14T13:43:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=12731"},"wordCount":192,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CRO \/ CMO \/ CDMO","Finance","HKG: 3759","Pharmaron","Rxilient Biohub","SHE: 300759"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=12731#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=12731","url":"https:\/\/flcube.com\/?p=12731","name":"Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-10-19T13:34:00+00:00","dateModified":"2024-11-14T13:43:00+00:00","description":"China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced plans to invest USD 10.5 million in establishing a joint venture (JV) named Rxilient Biohub Pte. Ltd. in Singapore. This strategic move marks Pharmaron's expansion into the Southeast Asian market, aiming to provide high-quality CDMO services in the region.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=12731#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=12731"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=12731#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12731"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12731\/revisions"}],"predecessor-version":[{"id":12734,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12731\/revisions\/12734"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}